Cytokinetics, Incorporated CYTK announced that the FDA approved its lead pipeline candidate, aficamten, for the treatment of ...

The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New ...

Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA ...

The authors present a useful agent-based model to study the tensile force generated by myosin mini-filaments in actin systems (bundles and networks); by numerically solving a mechanical model of ...

JUPITER, Fla., July 7, 2025 /PRNewswire/ -- Myosin Therapeutics, a clinical-stage biotechnology company advancing first-in-class therapies targeting molecular motor proteins, announced the publication ...

Center for Biophysics and Computational Biology and Physics Department, University of Illinois, Urbana, Illinois 61801, and Department of Physiology, University of Pennsylvania School of Medicine, ...

Cells use the polymerization of actin alone to create some types of movement, but many other forms of movement require interplay between actin and an enzyme called ...

Smooth muscle myosin II (SMII), the main motor protein in vascular smooth muscle cells (VSMC), generates the contractile forces crucial to VSMC function. SMII filaments assemble into bundles that bind ...

Myosin II is a biomolecular machine that is responsible for muscle contraction. Myosin II motors act cooperatively: during muscle contraction, multiple motors bind to a single actin filament and pull ...

Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States The contractile ring, which plays critical roles in cytokinesis ...